CLINICAL_TRIALS
withdrawal
· 2012-05-01
Clinical Trial Update: Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset Seizures [Phase 2]
Summary
A Phase 2 trial evaluating BGG492 as adjunctive therapy in patients with refractory partial-onset seizures has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Novartis | Conditions: Partial Onset Seizures | Phase 2 | Status: WITHDRAWN